Previous 10 | Next 10 |
Viveve Medical (NASDAQ: VIVE ) +109% on robust volume on no particular news. More news on: Viveve Medical, Inc., Achillion Pharmaceuticals, Inc., Ideal Power Inc., Stocks on the move, Read more ...
SEATTLE and ENCINO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, and The Dr. Susan Love Research Foundation, an...
SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast condi...
Atossa Genetics (NASDAQ: ATOS ) is up 2% premarket on announcing preliminary results from its Phase 1 study of its modified-release tablet form of oral Endoxifen. All objectives were successfully met. More news on: Atossa Genetics Inc., Healthcare stocks news, ...
SEATTLE, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported preliminary results from its Phase 1 study of its...
The following slide deck was published by Atossa Genetics Inc. in conjunction with this Read more ...
SEATTLE, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO and General Counsel of Atoss...
SEATTLE, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that all participant activities have been comple...
Atossa Genetics (NASDAQ: ATOS ): Q2 GAAP EPS of -$0.80 misses by $0.32 . More news on: Atossa Genetics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SEATTLE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the second quarter ended Ju...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...